Table 3 Association of CEM characteristics with malignant AD
Characteristics | Benign | Malignant | Sensitivity (%) | Specificity (%) | PPV# (%) | NPV* (%) | |
|---|---|---|---|---|---|---|---|
2D/Tomosynthesis detected | DBT detected | 25/32 (78.13%) | 5/17 (29.41%) | 70.6 | 78.1 | 63.2 | 83.3 |
2D and DBT detected | 7/32 (21.87%) | 12/17 (70.59%) | |||||
Enhancement | Absent | 9/32 (28.12%) | 0/17 (0%) | 100 | 28.12 | 42.5 | 100 |
Present | 23/32 (71.88%) | 17/17 (100%) | |||||
Density of enhancement | Absent/mild | 26/32 (81.25%) | 2/17 (11.76%) | 88.2 | 81.3 | 71.4 | 92.9 |
Moderate/marked | 6/32 (18.75%) | 15/17 (88.24%) | |||||
Enhancement Size (in cm) | ≤ 0.95 | 17/23 (73.92%) | 5/17 (29.41%) | 70.6 | 73.9 | 66.7 | 77.3 |
> 0.95 | 6/23 (26.08%) | 12/17 (70.59%) | |||||
Contrast/Tomo (C/T) ratio | ≤ 1.31 | 20/23 (86.96%) | 4/17 23.53%) | 76.5 | 87 | 81.3 | 83.3 |
> 1.31 | 3/23 (13.04%) | 13/17 (76.47%) | |||||
Enhancing morphology | Non-mass enhancement | 21/23 (91.30%) | 4/17 (23.53%) | 76.5 | 91.3 | 86.7 | 84 |
Mass | 2/23 (8.70%) | 13/17 (76.47%) | |||||
Relative change in density—early versus delayed | Increase/no change | 23/23 (100%) | 9/17 (52.95%) | 47.1 | 100 | 100 | 71.9 |
Decrease | 0/23 (0%) | 8/17 (47.05%) |